NGM Biopharmaceuticals (NYSE:NGM) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $30.33.

Several equities analysts recently issued reports on the stock. Raymond James boosted their target price on shares of NGM Biopharmaceuticals from $31.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 14th. Zacks Investment Research lowered shares of NGM Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 19th. B. Riley reiterated a “buy” rating and set a $30.00 price objective on shares of NGM Biopharmaceuticals in a report on Thursday, May 21st. Citigroup dropped their price objective on shares of NGM Biopharmaceuticals from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Finally, BMO Capital Markets started coverage on shares of NGM Biopharmaceuticals in a report on Thursday, June 4th. They set an “outperform” rating and a $30.00 price objective on the stock.

In other news, insider Jin-Long Chen sold 25,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $21.65, for a total transaction of $541,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter Svennilson bought 14,850 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were acquired at an average cost of $12.40 per share, with a total value of $184,140.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at $248,000. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 527,877 shares of company stock valued at $7,133,614.

Several large investors have recently bought and sold shares of NGM. Sunbelt Securities Inc. bought a new stake in NGM Biopharmaceuticals in the 4th quarter worth about $7,165,000. Bank of Montreal Can grew its position in shares of NGM Biopharmaceuticals by 412.9% during the 4th quarter. Bank of Montreal Can now owns 3,072 shares of the company’s stock valued at $57,000 after acquiring an additional 2,473 shares during the period. Sowell Financial Services LLC bought a new position in shares of NGM Biopharmaceuticals during the 4th quarter valued at approximately $61,000. Acadian Asset Management LLC bought a new position in shares of NGM Biopharmaceuticals during the 1st quarter valued at approximately $66,000. Finally, SG Americas Securities LLC bought a new position in shares of NGM Biopharmaceuticals during the 4th quarter valued at approximately $101,000.

NGM stock traded down $2.79 during midday trading on Tuesday, hitting $19.58. The stock had a trading volume of 711,100 shares, compared to its average volume of 343,334. NGM Biopharmaceuticals has a 1-year low of $8.81 and a 1-year high of $23.95. The business has a fifty day moving average price of $21.24 and a two-hundred day moving average price of $17.86.

NGM Biopharmaceuticals (NYSE:NGM) last released its earnings results on Wednesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). The company had revenue of $24.36 million for the quarter, compared to analyst estimates of $19.92 million.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome.

Featured Story: Cost of Debt

Analyst Recommendations for NGM Biopharmaceuticals (NYSE:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.